Improved Hypertension Control with the Imidazoline Agonist Moxonidine in a Multinational Metabolic Syndrome Population: Principal Results of the MERSY Study

Table 1

Summary demographic details of the intent-to-treat (ITT) population.

Total patients	𝑁=5603
Sex (𝑛=5554)
Male	2793 (50.2%)
Female	2772 (49.8%)
Age (yrs) (𝑛=5554)
<40	397 (7.1%)
40–49	1045 (18.8%)
50–59	1854 (33.4%)
60–69	1458 (26.2%)
>69	804 (14.5%)
<65	4102 (73.9%)
≥65	1452 (26.1%)
Menopause status (𝑛=2615)
Postmenopausal	1856 (71.0%)
Non postmenopausal	759 (29.0%)
Height (mean ± SD, cm) (𝑛=5464)	168.1 ± 8.9
Weight (mean ± SD, kg) (𝑛=5464)	91.9 ± 15.6
BMI (mean ± SD, kg/m^2) (𝑛=5464)	32.5 ± 5.0
Waist circumference (mean ± SD, cm) (𝑛=5195)	104.6 ± 13.3
Hip circumference (mean ± SD, cm) (𝑛=4722)	107.7 ± 13.7
Race/ethnicity (𝑛=4815)
White	2312 (48.0%)
American Indian or Alaska native	1496 (31.1%)
Asian	835 (17.3%)
Black of African heritage or African American	149 (3.1%)
Native Hawaiian or other Pacific Islander	17 (0.4%)
Aboriginal/Torres Strait Islander	6 (0.1%)
Smoker status (𝑛=5453)
Yes	1292 (23.7%)
No	4161 (76.3%)